All In Biotech

Drug Trial Radar · NCT06760546

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Sep 23, 2025

Primary completion

Mar 13, 2027

Study completion Mar 13, 2028

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how well setmelanotide works and how safe it is, patients with cHO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 26 weeks on a therapeutic regimen.

Conditions

  • Hypothalamic Obesity
  • Multiple Pituitary Hormone Deficiency Genetic Form
  • Septo-Optic Dysplasia
  • Optic Nerve Hypoplasia
  • Childhood-onset Combined Pituitary Hormone Deficiency
  • Pituitary Stalk Interruption Syndrome

Interventions

  • SetmelanotideDrug

    Solution for daily subcutaneous injection

  • PlaceboDrug

    Placebo matched to setmelanotide for daily subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean % change in BMITime frame: From Baseline after 26 weeks on a therapeutic regimen

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Lurie Children's Hospital

    Chicago, Illinois · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Children's Minnesota

    Saint Paul, Minnesota · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Seattle Children's Research Institute

    Seattle, Washington · Recruiting

  • Hull Royal Infirmary

    Hull, United Kingdom · Recruiting

  • UCL Great Ormond Street Institute of Child Health

    London, Greater London, United Kingdom · Recruiting

  • Birmingham Women and Children's Hospital NHS Trust

    Birmingham, West Midlands, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.